|
78 Companies |
|
132 Products |
|
132 Products |
|
108 Mechanisms of Action |
|
1 Trial |
|
1044 News |
|
| 12345678910111213...2122» |
- | Enrollment change, Trial termination: IMPROVA: Improving Outcomes in Vascular Access (clinicaltrials.gov) - Apr 26, 2019
P=N/A, N=32, Terminated, Sponsor: University Hospital Birmingham
N=200 --> 32 | Not yet recruiting --> Terminated; similar study in USA published with same protocol
- | Clinical data, Trial completion, Phase classification, Enrollment change: MFD: More Frequent Dialysis (>3 Treatments Per Week) (clinicaltrials.gov) - Apr 21, 2019
P=N/A, N=46, Completed, Sponsor: Satellite Healthcare
N=200 --> 32 | Not yet recruiting --> Terminated; similar study in USA published with same protocol Recruiting --> Completed | Phase classification: P4 --> PN/A | N=300 --> 46
- | Trial completion, Enrollment change: Comparison of Dialysis Therapies on Cognitive Function (clinicaltrials.gov) - Apr 21, 2019
P=N/A, N=17, Completed, Sponsor: Satellite Healthcare
Recruiting --> Completed | Phase classification: P4 --> PN/A | N=300 --> 46 Recruiting --> Completed | N=100 --> 17
- | mycophenolate mofetil / Generic mfg.
Enrollment change, Trial termination: ONEmreg12: The ONE Study M Reg Trial (clinicaltrials.gov) - Apr 20, 2019
P1/2, N=8, Terminated, Sponsor: University of Regensburg
Recruiting --> Completed | N=100 --> 17 N=16 --> 8 | Recruiting --> Terminated; Insufficient rate of patient recruitment and treatment.
- | Enrollment change, Trial termination: Impact of Exercise on Cognitive Impairment in End-Stage Renal Disease (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=20, Terminated, Sponsor: University of Kansas Medical Center
N=16 --> 8 | Recruiting --> Terminated; Insufficient rate of patient recruitment and treatment. N=15 --> 20 | Suspended --> Terminated; Funding has expired
- Enrollment change, Trial termination: Reveal LINQ™ Evaluation of Fluid (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=9, Terminated, Sponsor: Medtronic Cardiac Rhythm and Heart Failure
N=15 --> 20 | Suspended --> Terminated; Funding has expired N=70 --> 9 | Recruiting --> Terminated; Study terminated as sufficient data was collected to determine if impedance measurements with the LINQ™ device could track body fluid changes.
- | Phase classification: Rapid Renal Sympathetic Denervation for Resistant Hypertension (clinicaltrials.gov) - Mar 2, 2019
P=N/A, N=50, Completed, Sponsor: Medtronic Endovascular
N=70 --> 9 | Recruiting --> Terminated; Study terminated as sufficient data was collected to determine if impedance measurements with the LINQ™ device could track body fluid changes. Phase classification: P2 --> P=N/A
- | Trial completion, Trial completion date: Adipose Tissue Function After Pancreas Transplantation (clinicaltrials.gov) - Mar 1, 2019
P=N/A, N=15, Completed, Sponsor: The University of Texas Medical Branch, Galveston
Phase classification: P2 --> P=N/A Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Feb 2019
- | Enrollment change, HEOR, Cost effectiveness: Propaten Randomized Investigation on Cost-benefit and Efficacy (clinicaltrials.gov) - Feb 27, 2019
P=N/A, N=103, Terminated, Sponsor: The University of Texas Health Science Center, Houston
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Feb 2019 N=200 --> 103
- | Trial suspension: Impact of Exercise on Cognitive Impairment in End-Stage Renal Disease (clinicaltrials.gov) - Feb 25, 2019
P=N/A, N=15, Suspended, Sponsor: University of Kansas Medical Center
N=200 --> 103 Recruiting --> Suspended
- | rosuvastatin / Generic mfg.
Trial completion: Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula (clinicaltrials.gov) - Feb 19, 2019
P2, N=60, Completed, Sponsor: National Cheng-Kung University Hospital
Recruiting --> Suspended Recruiting --> Completed
- | mycophenolate mofetil / Generic mfg.
Trial completion, Trial primary completion date: ONETreg1: The ONE Study UK Treg Trial (clinicaltrials.gov) - Jan 25, 2019
P1/2, N=15, Completed, Sponsor: Guy's and St Thomas' NHS Foundation Trust
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2017
- | aspirin / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients (clinicaltrials.gov) - Jan 17, 2019
P4, N=0, Withdrawn, Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2017 N=250 --> 0 | Trial completion date: Feb 2013 --> Jan 2018 | Recruiting --> Withdrawn | Trial primary completion date: Feb 2011 --> Jan 2018
- | Enrollment change: Immune Development in Pediatric Transplantation (IMPACT) (clinicaltrials.gov) - Jan 4, 2019
P=N/A, N=125, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=250 --> 0 | Trial completion date: Feb 2013 --> Jan 2018 | Recruiting --> Withdrawn | Trial primary completion date: Feb 2011 --> Jan 2018 N=75 --> 125
- | mycophenolate mofetil / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: ONEatDC: The ONE Study ATDC Trial (clinicaltrials.gov) - Jan 2, 2019
P1/2, N=11, Completed, Sponsor: Nantes University Hospital
N=75 --> 125 Recruiting --> Completed | N=16 --> 11 | Trial completion date: Oct 2019 --> Nov 2018 | Trial primary completion date: Jun 2019 --> Nov 2018
- | Trial completion, Trial completion date: NOCTX: Arterial Calcifications in Nocturnal Hemodialysis and Renal Transplantation Versus Conventional Dialysis (clinicaltrials.gov) - Dec 20, 2018
P=N/A, N=184, Completed, Sponsor: Dianet Dialysis Centers
Recruiting --> Completed | N=16 --> 11 | Trial completion date: Oct 2019 --> Nov 2018 | Trial primary completion date: Jun 2019 --> Nov 2018 Active, not recruiting --> Completed | Trial completion date: May 2019 --> Dec 2018
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Nulojix (belatacept) / BMS
Enrollment change, Trial withdrawal: BelatPilot: Belatacept in Kidney Transplantation of Moderately Sensitized Patients (clinicaltrials.gov) - Dec 17, 2018
P4, N=0, Withdrawn, Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Completed | Trial completion date: May 2019 --> Dec 2018 N=20 --> 0 | Recruiting --> Withdrawn
- | Trial completion, Trial completion date: Improving Evidence-Based Primary Care for Chronic Kidney Disease (clinicaltrials.gov) - Dec 12, 2018
P=N/A, N=27000, Completed, Sponsor: American Academy of Family Physicians
N=20 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed | Trial completion date: Jun 2016 --> Jan 2016
- | Trial completion, Enrollment change: Imaging Modalities in Detection of Coronary Artery Disease in End-stage Renal Disease Patients (clinicaltrials.gov) - Dec 10, 2018
P=N/A, N=189, Completed, Sponsor: University of Nebraska
Recruiting --> Completed | Trial completion date: Jun 2016 --> Jan 2016 Not yet recruiting --> Completed | N=75 --> 189
- | Enrollment change, Trial primary completion date: Renal Denervation to Improve Outcomes in Patients With End-stage Renal Disease (clinicaltrials.gov) - Nov 5, 2018
P=N/A, N=3, Active, not recruiting, Sponsor: Baker IDI Heart and Diabetes Institute
Not yet recruiting --> Completed | N=75 --> 189 N=100 --> 3 | Trial primary completion date: Dec 2016 --> Dec 2022
- | Trial termination, HEOR, Cost effectiveness: Propaten Randomized Investigation on Cost-benefit and Efficacy (clinicaltrials.gov) - Oct 16, 2018
P=N/A, N=200, Terminated, Sponsor: The University of Texas Health Science Center, Houston
N=100 --> 3 | Trial primary completion date: Dec 2016 --> Dec 2022 Active, not recruiting --> Terminated; Results from futility analysis conducted at planned interim time-point did not meet the study criteria for continuation.
- | Soliris (eculizumab) / AstraZeneca
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury (clinicaltrials.gov) - Sep 1, 2018
P2, N=57, Completed, Sponsor: Russian Academy of Medical Sciences
Active, not recruiting --> Terminated; Results from futility analysis conducted at planned interim time-point did not meet the study criteria for continuation. Recruiting --> Completed | N=40 --> 57 | Trial completion date: May 2019 --> Dec 2017 | Trial primary completion date: Mar 2018 --> Apr 2017
- | Trial completion, Trial completion date: Effect of Renal Transplantation on Obstructive Sleep Apnea in End Stage Renal Disease Patients (SASinTx) (clinicaltrials.gov) - Aug 15, 2018
P=N/A, N=40, Completed, Sponsor: Centre Hospitalier Universitaire Vaudois
Recruiting --> Completed | N=40 --> 57 | Trial completion date: May 2019 --> Dec 2017 | Trial primary completion date: Mar 2018 --> Apr 2017 Recruiting --> Completed | Trial completion date: Mar 2018 --> Dec 2017
- | bupropion sustained-release / Generic mfg., fluoxetine / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Bupropion for Depression in ESRD Patients on Hemodialysis (clinicaltrials.gov) - Jul 17, 2018
P4, N=1, Terminated, Sponsor: University of Arkansas
Recruiting --> Completed | Trial completion date: Mar 2018 --> Dec 2017 N=40 --> 1 | Trial completion date: Dec 2018 --> Mar 2018 | Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Mar 2018; Study stopped due to difficulty recruiting
- ||| Nulojix (belatacept) / BMS
Trial completion: Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores (clinicaltrials.gov) - Jun 14, 2018
P=N/A, N=20, Completed, Sponsor: University of Maryland
N=40 --> 1 | Trial completion date: Dec 2018 --> Mar 2018 | Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Mar 2018; Study stopped due to difficulty recruiting Active, not recruiting --> Completed
- | mycophenolate mofetil / Generic mfg.
Trial completion date, Trial primary completion date: ONEmreg12: The ONE Study M Reg Trial (clinicaltrials.gov) - May 3, 2018
P1/2, N=16, Recruiting, Sponsor: University of Regensburg
Active, not recruiting --> Completed Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Trial completion: Your Path to Transplant: A Randomized Control Trial of A Tailored Computer Education Intervention for Living Donor Kidney Transplant (clinicaltrials.gov) - May 1, 2018
P=N/A, N=815, Completed, Sponsor: University of California, Los Angeles
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: Predictive Value of PIIINP Urinary for the Development of Chronic Renal Failure in Patients With Cystic Fibrosis After Lung Transplantation (MUCO-IRC) (clinicaltrials.gov) - Apr 23, 2018
P=N/A, N=45, Terminated, Sponsor: Nantes University Hospital
Active, not recruiting --> Completed Trial completion date: Jun 2019 --> Apr 2018 | Trial primary completion date: Jun 2019 --> Apr 2018
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial completion, Trial completion date, Trial primary completion date: PREDICTt: PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease (clinicaltrials.gov) - Apr 18, 2018
P3, N=476, Completed, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Trial completion date: Jun 2019 --> Apr 2018 | Trial primary completion date: Jun 2019 --> Apr 2018 Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Dec 2017 | Trial primary completion date: Jun 2017 --> Dec 2017
- | Campath (alemtuzumab) / Sanofi, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation (clinicaltrials.gov) - Apr 2, 2018
P4, N=236, Completed, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Dec 2017 | Trial primary completion date: Jun 2017 --> Dec 2017 Active, not recruiting --> Completed
- | Kineret (anakinra) / SOBI
Enrollment change: INSPIRED: Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2 (clinicaltrials.gov) - Apr 2, 2018
P2, N=33, Completed, Sponsor: VA Office of Research and Development
Active, not recruiting --> Completed N=24 --> 33
- || Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Phase classification, Enrollment change: Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans (clinicaltrials.gov) - Mar 27, 2018
P2/3, N=49, Completed, Sponsor: University of Michigan
N=24 --> 33 Active, not recruiting --> Completed | Phase classification: P4 --> P2/3 | N=35 --> 49
- | Trial completion, Enrollment change: Transplant Navigator Dissemination (clinicaltrials.gov) - Mar 22, 2018
P=N/A, N=1926, Completed, Sponsor: Catherine Sullivan
Active, not recruiting --> Completed | Phase classification: P4 --> P2/3 | N=35 --> 49 Active, not recruiting --> Completed | N=1200 --> 1926
- | Enrollment change, Trial withdrawal, Metastases: DIACAL: High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease (clinicaltrials.gov) - Mar 21, 2018
P2, N=0, Withdrawn, Sponsor: IRCCS Policlinico S. Matteo
Active, not recruiting --> Completed | N=1200 --> 1926 N=16 --> 0 | Completed --> Withdrawn
- | Trial completion, Metastases: DIACAL: High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease (clinicaltrials.gov) - Mar 12, 2018
P2, N=16, Completed, Sponsor: IRCCS Policlinico S. Matteo
N=16 --> 0 | Completed --> Withdrawn Suspended --> Completed
- | Phase classification, Enrollment change, Trial termination: Anesthetic Technique for AV Fistulae Creation (clinicaltrials.gov) - Mar 5, 2018
P=N/A, N=10, Terminated, Sponsor: Montefiore Medical Center
Suspended --> Completed Phase classification: P4 --> P=N/A | N=175 --> 10 | Recruiting --> Terminated; Low Accural Rate
- | Enrollment change: Disc Edema in Patients With Chronic Kidney Disease (clinicaltrials.gov) - Feb 28, 2018
P=N/A, N=0, Withdrawn, Sponsor: University of Mississippi Medical Center
Phase classification: P4 --> P=N/A | N=175 --> 10 | Recruiting --> Terminated; Low Accural Rate N=323 --> 0
- | Enrollment change: Communicating About Choices in Transplantation (clinicaltrials.gov) - Feb 28, 2018
P=N/A, N=20, Completed, Sponsor: Virginia Commonwealth University
N=323 --> 0 N=158 --> 20
- |||| Simulect (basiliximab) / Novartis
Trial completion, Trial completion date: TRANSFORMt: Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (clinicaltrials.gov) - Feb 28, 2018
P4, N=2041, Completed, Sponsor: Novartis Pharmaceuticals
N=158 --> 20 Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018
- | Enrollment change: Evaluation of a Patient Navigation System to Reduce Time to Waitlisting for Potential Kidney Transplant Recipients (clinicaltrials.gov) - Feb 22, 2018
P=N/A, N=401, Completed, Sponsor: Emory University
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018 N=800 --> 401
- | Trial completion: Communicating About Choices in Transplantation (clinicaltrials.gov) - Feb 20, 2018
P=N/A, N=158, Completed, Sponsor: Virginia Commonwealth University
N=800 --> 401 Active, not recruiting --> Completed
- | Trial primary completion date: A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement (clinicaltrials.gov) - Feb 6, 2018
P=N/A, N=6, Terminated, Sponsor: Diaxamed LLC
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Jun 2017
- | warfarin / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Vitamin K Supplementation in Patients on Hemodialysis (clinicaltrials.gov) - Feb 6, 2018
P2, N=3, Completed, Sponsor: University Health Network, Toronto
Trial primary completion date: Dec 2017 --> Jun 2017 Recruiting --> Completed | N=15 --> 3 | Trial primary completion date: Dec 2018 --> Dec 2017 | Trial completion date: Dec 2018 --> Dec 2017
- Cubicin (daptomycin) / Merck (MSD)
Phase classification: Study to Evaluate Daptomycin Given During Dialysis and After Dialysis (clinicaltrials.gov) - Feb 6, 2018
P1, N=16, Completed, Sponsor: Cubist Pharmaceuticals LLC
Recruiting --> Completed | N=15 --> 3 | Trial primary completion date: Dec 2018 --> Dec 2017 | Trial completion date: Dec 2018 --> Dec 2017 Phase classification: P1/2 --> P1
- | Trial completion, Trial primary completion date: Arteriovenous Fistula Tissue Bank for Pre- and Post-Fistula Placement Specimens (clinicaltrials.gov) - Feb 5, 2018
P=N/A, N=43, Completed, Sponsor: University of Nebraska
Phase classification: P1/2 --> P1 Recruiting --> Completed | Trial primary completion date: Nov 2011 --> Nov 2012
- ticagrelor / Generic mfg.
Enrollment change: Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects (clinicaltrials.gov) - Jan 17, 2018
P1, N=27, Completed, Sponsor: AstraZeneca
Recruiting --> Completed | Trial primary completion date: Nov 2011 --> Nov 2012 N=56 --> 27
- | Trial primary completion date: Impact of Exercise on Cognitive Impairment in End-Stage Renal Disease (clinicaltrials.gov) - Dec 29, 2017
P=N/A, N=15, Recruiting, Sponsor: University of Kansas Medical Center
N=56 --> 27 Trial primary completion date: Dec 2017 --> Dec 2018
- | Trial completion, Phase classification, Enrollment change, Trial primary completion date: Treatment of Masked Hypertension (clinicaltrials.gov) - Dec 29, 2017
P3, N=4, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Completed | Phase classification: P4 --> P3 | N=50 --> 4 | Trial primary completion date: Dec 2018 --> Dec 2017
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Enrollment change, Trial primary completion date: Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation (clinicaltrials.gov) - Dec 22, 2017
P1/2, N=41, Completed, Sponsor: Stanley Jordan, MD
Recruiting --> Completed | Phase classification: P4 --> P3 | N=50 --> 4 | Trial primary completion date: Dec 2018 --> Dec 2017 Active, not recruiting --> Completed | N=75 --> 41 | Trial primary completion date: Jan 2018 --> Jul 2017
- | Trial completion, Trial primary completion date, Surgery: PRECARDIO: Chronic Kidney Disease in Teenagers With Congenital Cardiac Disease (clinicaltrials.gov) - Dec 21, 2017
P=N/A, N=120, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed | N=75 --> 41 | Trial primary completion date: Jan 2018 --> Jul 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2015